Evogene Ltd. filings document a foreign private issuer whose disclosures are centered on computational chemistry, ChemPass AI™, and small-molecule product development for pharmaceutical and agricultural markets. Form 6-K reports furnish quarterly and annual financial results, unaudited consolidated financial statements, operating and financial review materials, and presentations incorporated by reference into registration statements.
The filing record also covers material agreements and corporate events tied to Evogene's subsidiaries and platform strategy, including Biomica's BMC128 licensing disclosure, management changes, Nasdaq minimum-bid-price correspondence, and capital-structure disclosures through Form F-3 and Form S-8 references. These documents describe governance and financing context for EVGN ordinary shares and the company's operating subsidiaries.
Evogene Ltd. investor and director Leon Recanati filed a Schedule 13D reporting beneficial ownership of 894,836 ordinary shares, or 5.7% of Evogene’s outstanding ordinary shares. This includes 883,886 shares held directly and 10,950 shares underlying options that are currently exercisable or exercisable within 60 days of August 4, 2026.
On August 4, 2026, he purchased 800,000 ordinary shares in open-market transactions at a weighted average price of $0.50 per share, for aggregate consideration of approximately $400,000, using personal funds. Recanati states he acquired the shares for investment purposes and, as a director, intends to vote all shares he beneficially owns in favor of the slate of director nominees put forward by Evogene’s current board at the 2026 annual general meeting, which includes a contested director election. He indicates he may buy or sell additional Evogene securities in the future depending on conditions.
An investor group associated with L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman and Ron Yair Peled reported an increased stake in Evogene Ltd. Following open-market purchases between August 3 and August 6, 2026, Pure Capital acquired 216,300 additional American Depositary Shares (ADSs) using working capital.
Based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, the group now reports beneficial ownership of 2,524,400 shares, representing approximately 15.98% of Evogene’s outstanding share capital. Pure Capital has sole dispositive power over 1,968,300 ADSs and 56,100 Ordinary Shares, or about 12.81%, while Invest Pro has sole dispositive power over 500,000 ADSs, or about 3.16%. Voting power over 2,468,300 ADSs and 56,100 Ordinary Shares is shared under an oral voting agreement.
Evogene Ltd. director Leon Recanati purchased 800,000 Ordinary Shares on August 4, 2026 in multiple transactions at a weighted average price of $0.50 per share, increasing his direct ownership to 883,886 Ordinary Shares. He also reports existing stock option positions for informational purposes.
Evogene Ltd. has called its 2026 annual general meeting for 12:00 p.m. (Israel time) on September 4, 2026, with a record date of August 11, 2026. Shareholders must choose between the incumbent seven-member Evogene Slate and a four-member Pure Capital Slate for the board, and may cast a vote only “FOR” one slate.
Other proposals seek to increase authorized share capital from NIS 6,000,000 (30,000,000 ordinary shares) to NIS 30,000,000 (150,000,000 ordinary shares), approve a framework for a reverse share split between 1-for-2 and 1-for-15 to help satisfy Nasdaq’s $1.00 minimum bid requirement, and reappoint Kost Forer Gabbay & Kasierer as independent auditors.
The board cites prior restructuring, lower expected annual cash burn and asset divestiture proceeds as support for its strategy and recommends voting for the Evogene Slate and all other proposals. Ms. Olga Nissan has stepped down as VP Business Development effective July 31, 2026.
Evogene Ltd. shareholders L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd., Kfir Silberman and Ron Yair Peled report updated holdings and actions in Amendment No. 2 to their Schedule 13D. Together they report shared voting power over 2,252,000 ADSs and 56,100 Ordinary Shares, or about 17.41% of Evogene’s share capital, based on at least 13,258,521 Ordinary Shares held by non-affiliates as of July 17, 2026; the actual percentage may be lower if more shares are outstanding.
They report that Pure Capital acquired an additional 80,000 ADSs using working capital in open‑market transactions. They also describe a July 26, 2026 email to Evogene reiterating their demand to convene a special general meeting of shareholders, rejecting certain settlement proposals, reaffirming intentions outlined in a prior demand letter, requesting draft meeting and proxy materials, and reserving all legal rights.
L.I.A. Pure Capital Ltd., Invest Pro Shukai Hon Ltd. and related individuals filed Amendment No. 1 to their Schedule 13D on Evogene Ltd. after Pure Capital purchased 202,000 additional American Depositary Shares (ADSs) using working capital. The reporting persons now beneficially own 2,228,100 Ordinary Shares/ADSs, representing about 16.81% of Evogene’s share capital.
This percentage is calculated using 13,258,521 Ordinary Shares reported as held by non-affiliates as of July 17, 2026, and they state the actual percentage ownership may be lower. Pure Capital has sole dispositive power over 1,672,000 ADSs and 56,100 Ordinary Shares, while Invest Pro has sole dispositive power over 500,000 ADSs, with voting power shared under an oral voting agreement. The individuals may be deemed beneficial owners through their control of these entities but expressly disclaim beneficial ownership beyond their pecuniary interests and the existence of any Section 13(d) group.
EVGN is amending its existing at-the-market equity program with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of its ordinary shares from $2,926,500 to $3,288,113 under its Form F-3 shelf registration.
The ordinary shares, par value 0.2 NIS, may be sold from time to time in transactions deemed “at the market offerings” under Rule 415, with A.G.P. acting as sales agent on a best efforts basis for a 3.0% commission on gross sales. To date, EVGN has sold approximately $1,753,025.13 of ordinary shares under the Sales Agreement. The aggregate market value of public float was about $9,864,339.62 as of July 17, 2026, and the remaining capacity to sell securities under General Instruction I.B.5. of Form F-3 was $1,535,088.08.
Evogene Ltd. reports increasing the maximum aggregate offering price of ordinary shares available under its at-the-market Sales Agreement with A.G.P./Alliance Global Partners from $2,926,500 to $3,288,113, enabling potential issuance of an additional $361,613 of ordinary shares, supported by a legal opinion.
The company also updates its risk factors to describe an ongoing campaign by activist shareholders who filed a Schedule 13D on July 10, 2026 and requested a shareholder meeting to replace most directors. Evogene states that such activism and any resulting proxy contest could materially and adversely affect its business, financial condition, results of operations and the market price of its ordinary shares, and incorporates this disclosure into certain existing registration statements.
Evogene Ltd. shareholders L.I.A. Pure Capital Ltd. and Invest Pro Shukai Hon Ltd., together with their principals, disclosed significant stakes and an activist campaign. Pure Capital and its controlling shareholder, Kfir Silberman, beneficially own 1,526,100 Evogene Ordinary Shares and ADSs, representing 12.61% of the outstanding share capital based on 12,104,457 Ordinary Shares outstanding as of June 3, 2026. Invest Pro and its owner, Ron Yair Peled, beneficially own 500,000 ADSs, representing 4.13% of the outstanding share capital.
On July 10, 2026, these holders sent Evogene a letter demanding a special general meeting of shareholders to vote on removing current directors other than Ofer Haviv, electing their own nominees, and approving compensation, exemption, indemnification and insurance arrangements for those nominees. The reporting persons have an oral agreement to share voting power over 2,026,100 shares while each retains sole dispositive power over its own holdings and intend to formalize this in a written voting agreement.
Evogene Ltd. provides an overview of its ChemPass AI platform, which uses generative AI to design and optimize novel small molecules for pharmaceutical and agricultural applications. The system combines three tools—PointHit, ActiveSearch and LeadOpGPT—to screen ultra-large libraries and fine‑tune candidates across potency, selectivity, solubility and other properties.
The presentation highlights collaborations with Google Cloud to build a generative AI model trained on 38 billion molecular structures and to integrate AI agents that automate design–make–test–analyze cycles. Evogene outlines a pharma pipeline spanning oncology, immunology, neurology and metabolic disease projects, including programs in aggressive breast cancer and gout‑related metabolic conditions.
In agriculture, work is conducted through its AgPlenus subsidiary, targeting new herbicides and fungicides such as a wheat blotch program in a European fungicide market exceeding $1.2 billion annually. The company emphasizes co‑development and out‑licensing business models with academic groups, biotech firms and global crop protection companies.